Clinical trial

Study of Verinurad in Heart Failure With Preserved Ejection Fraction

NCT04327024

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2020-05-19

PhasePHASE2

Study timeline

Study start (actual)2020-05-19Date precision: day

Registry last updated2023-06-29

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Heart Failure With Preserved Ejection Fraction (HFpEF)unresolved

Interventions

VerinuradDRUG

AllopurinolDRUG · verified · RxNorm: allopurinol

Placebo for verinuradDRUG

Placebo for allopurinolDRUG

Sponsors & collaborators

AstraZenecalead sponsor

Mapped research locations

SeoulSouth Korea4 QuébecQuebec, Canada4 WarsawPoland3 BerlinGermany2 Saint PetersburgRussia2 SofiaBulgaria2 MiamiFlorida, United States1 Winston-SalemNorth Carolina, United States1 ViennaAustria1 TorranceCalifornia, United States1 NorfolkVirginia, United States1 LublinPoland1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04327024 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.